Tilmicosin
Names | |
---|---|
IUPAC name [(2R,3R,4E,6E,9R,11R,12S,13S,14R)-12-{[3,6-Dideoxy-3-(dimethylamino)-β-D-glucopyranosyl]oxy}-11-{2-[(3R,5S)-3,5-dimethylpiperidin-1-yl]ethyl}-2-ethyl-14-hydroxy-5,9,13-trimethyl-8,16-dioxooxacyclohexadeca-4,6-dien-3-yl]methyl 6-deoxy-2,3-di-O-methyl-β-D-allopyranoside | |
Other names Micotil; 20-Deoxy-20-(3,5-dimethylpiperidin-1-yl)-desmycosin[1] | |
Identifiers | |
3D model (JSmol) | |
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.167.324 |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C46H80N2O13 | |
Molar mass | 869.147 g·mol−1 |
566 mg/mL[1] | |
Pharmacology | |
QJ01FA91 (WHO) | |
Legal status | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Tilmicosin is a macrolide antibiotic. It is distributed under the brand name Micotil. It is used in veterinary medicine for the treatment of bovine respiratory disease and enzootic pneumonia caused by Mannheimia (Pasteurella) haemolytica in sheep.[3] In humans, Tilmicosin causes fatal cardiotoxic effects at amounts greater than 1 milliliter when injected, something most commonly seen in veterinary personnel and farmers. [4] Tilmicosin, like most macrolides, is a Calcium channel blocker. However, because Micotil is formulated for animals like cows, it has exceptionally more potent Ca channel blocking effects in humans with a dose of .5 mL causing significant poisoning and a dose of 5-6 ml being lethal.[5]
References
[edit]- ^ a b Tilmicosin, United Nations Food and Agriculture Organization
- ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
- ^ Micotil 300 New Animal Drug Application, United States Food and Drug Administration
- ^ Micotil (tilmicosin) - Adverse Drug Reactions - Veterinary Drugs, Veterinary Drugs Directorate
- ^ Gussow, Leon (July 2020). "Toxicology Rounds: An Animal Antibiotic Lethal to Humans in Tiny Doses". Emergency Medicine News. 42 (7): 22. doi:10.1097/01.EEM.0000688876.75898.6d. Retrieved 5 April 2023.